Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Company Overview - Inozyme Pharma is a clinical-stage biopharmaceutical company based in Boston, employing approximately 50 people [3] - The company focuses on developing therapeutics targeting the PPi-Adenosine Pathway, which is crucial for bone health and blood vessel function [3] - Inozyme's lead investigational therapy, INZ-701, is designed to treat ENPP1 Deficiency and is currently in late-stage clinical development [3] Acquisition Details - Inozyme Pharma has postponed its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to the announced acquisition by BioMarin Pharmaceutical Inc. [1] - If the acquisition is completed, there will be no Annual Meeting for public stockholders [2] - Should the acquisition not be completed, the Board of Directors will take necessary actions to convene the Annual Meeting at a later date [2] Additional Information - The acquisition process involves a tender offer, with relevant materials filed with the SEC by both Inozyme and BioMarin [5] - Investors and stockholders are encouraged to review the tender offer materials and related documents for important information regarding the acquisition [5]